CL2019003215A1 - Anticuerpos agonistas contra btla y sus usos. - Google Patents

Anticuerpos agonistas contra btla y sus usos.

Info

Publication number
CL2019003215A1
CL2019003215A1 CL2019003215A CL2019003215A CL2019003215A1 CL 2019003215 A1 CL2019003215 A1 CL 2019003215A1 CL 2019003215 A CL2019003215 A CL 2019003215A CL 2019003215 A CL2019003215 A CL 2019003215A CL 2019003215 A1 CL2019003215 A1 CL 2019003215A1
Authority
CL
Chile
Prior art keywords
antibodies against
agonist antibodies
btla
against btla
antibodies
Prior art date
Application number
CL2019003215A
Other languages
English (en)
Inventor
Shane Krummen Atwell
Victor H Obungu
Andrew Charles Vendel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2019003215A1 publication Critical patent/CL2019003215A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROPORCIONAN ANTICUERPOS QUE SE FIJAN A BTLA, Y MÉTODOS PARA USARLOS, EN DONDE DICHOS ANTICUERPOS SON ÚTILES COMO AGENTES PARA TRATAR AFECCIONES ASOCIADAS A LA ENFERMEDAD AUTOINMUNITARIA, QUE INCLUYEN EL TRATAMIENTO DE LUPUS.
CL2019003215A 2017-05-19 2019-11-08 Anticuerpos agonistas contra btla y sus usos. CL2019003215A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
CL2019003215A1 true CL2019003215A1 (es) 2020-04-13

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003215A CL2019003215A1 (es) 2017-05-19 2019-11-08 Anticuerpos agonistas contra btla y sus usos.

Country Status (25)

Country Link
US (2) US10604573B2 (es)
EP (1) EP3625257A1 (es)
JP (2) JP6790304B2 (es)
KR (3) KR102294051B1 (es)
CN (3) CN117402245A (es)
AR (1) AR111752A1 (es)
AU (2) AU2018269585B2 (es)
BR (1) BR112019021547A2 (es)
CA (2) CA3064518A1 (es)
CL (1) CL2019003215A1 (es)
CO (1) CO2019012756A2 (es)
CR (1) CR20190521A (es)
DO (1) DOP2019000293A (es)
EA (1) EA201992460A1 (es)
EC (1) ECSP19082184A (es)
JO (1) JOP20190261A1 (es)
MA (1) MA49133A (es)
MX (1) MX2019013604A (es)
MY (1) MY197425A (es)
NZ (1) NZ758360A (es)
PE (1) PE20191843A1 (es)
PH (1) PH12019502575A1 (es)
TW (4) TWI804044B (es)
WO (1) WO2018213113A1 (es)
ZA (1) ZA201906954B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
US20230391872A1 (en) * 2020-10-23 2023-12-07 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2023143565A1 (en) * 2022-01-29 2023-08-03 Hifibio (Hk) Limited Anti-btla antibodies and uses thereof in treating cancer
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
WO2004039394A1 (en) * 2002-10-25 2004-05-13 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2007334264A1 (en) * 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
AU2010276580A1 (en) * 2009-07-31 2012-03-15 Medarex, L.L.C. Fully human antibodies to BTLA
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
WO2016176583A1 (en) * 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体

Also Published As

Publication number Publication date
EA201992460A1 (ru) 2020-03-18
PH12019502575A1 (en) 2020-07-13
TWI804044B (zh) 2023-06-01
US10604573B2 (en) 2020-03-31
AR111752A1 (es) 2019-08-14
US20200239578A1 (en) 2020-07-30
AU2018269585B2 (en) 2021-09-02
KR102294051B1 (ko) 2021-08-27
KR20190140969A (ko) 2019-12-20
CR20190521A (es) 2020-01-06
JP2020518288A (ja) 2020-06-25
PE20191843A1 (es) 2019-12-31
DOP2019000293A (es) 2019-12-15
CN110621699B (zh) 2023-10-31
CN110621699A (zh) 2019-12-27
TWI677504B (zh) 2019-11-21
KR20220158847A (ko) 2022-12-01
WO2018213113A1 (en) 2018-11-22
US11396545B2 (en) 2022-07-26
MX2019013604A (es) 2019-12-18
CN117402244A (zh) 2024-01-16
EP3625257A1 (en) 2020-03-25
MA49133A (fr) 2020-03-25
AU2018269585A1 (en) 2019-10-31
JOP20190261A1 (ar) 2019-11-05
NZ758360A (en) 2022-10-28
ECSP19082184A (es) 2019-11-30
CO2019012756A2 (es) 2020-01-17
AU2021277743A1 (en) 2021-12-23
TW201904991A (zh) 2019-02-01
CA3064518A1 (en) 2018-11-22
CA3184628A1 (en) 2018-11-22
TW202334237A (zh) 2023-09-01
JP7072622B2 (ja) 2022-05-20
TW201946932A (zh) 2019-12-16
MY197425A (en) 2023-06-16
TW202233681A (zh) 2022-09-01
KR20210106033A (ko) 2021-08-27
JP6790304B2 (ja) 2020-11-25
BR112019021547A2 (pt) 2020-05-12
TWI747043B (zh) 2021-11-21
ZA201906954B (en) 2021-06-30
US20180334502A1 (en) 2018-11-22
JP2021019642A (ja) 2021-02-18
CN117402245A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
CL2019003215A1 (es) Anticuerpos agonistas contra btla y sus usos.
CL2017000651A1 (es) Anticuerpos anti-glucagón y sus usos
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
CL2017003404A1 (es) Compuestos antibacterianos
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
NI201700060A (es) Agonistas parciales del receptor de insulina
ECSP17070399A (es) Anticuerpos contra icos
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
ECSP17005276A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
ECSP19059553A (es) Anticuerpos anti-tgf-beta y su uso
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
NI201800134A (es) Anticuerpos antifactor de la coagulación xi
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
BR112019025372A2 (pt) Suplemento de ração animal, composição de ração animal, usos de um suplemento, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
ECSP17039183A (es) Agonistas parciales del receptor de insulina
ES1179009Y (es) Sujetador para el pene
SG11202001411UA (en) Method for tanning an animal skin with dialdehydes
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp
AR098780A1 (es) Proceso de obtención de micropartículas de quitosano
AR095235A1 (es) Anticuerpos dirigidos contra il-33 y sus usos